Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $18.30 Average PT from Analysts

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has been given an average rating of “Moderate Buy” by the eleven brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $18.30.

Several brokerages have issued reports on YMAB. Wedbush reissued an “outperform” rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, March 3rd. Brookline Capital Management assumed coverage on Y-mAbs Therapeutics in a report on Thursday, December 5th. They set a “buy” rating and a $17.00 price objective for the company. Morgan Stanley reduced their target price on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a research note on Wednesday, March 5th. Truist Financial lowered their target price on shares of Y-mAbs Therapeutics from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, March 5th. Finally, Bank of America reduced their price target on shares of Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 5th.

Insider Buying and Selling at Y-mAbs Therapeutics

In other news, insider Thomas Gad sold 10,810 shares of the firm’s stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $5.23, for a total value of $56,536.30. Following the sale, the insider now directly owns 202,721 shares in the company, valued at approximately $1,060,230.83. This trade represents a 5.06 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 22.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Acorn Capital Advisors LLC purchased a new stake in shares of Y-mAbs Therapeutics during the fourth quarter worth about $22,408,000. Caligan Partners LP increased its stake in Y-mAbs Therapeutics by 105.3% during the 3rd quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock valued at $15,718,000 after purchasing an additional 613,175 shares in the last quarter. State Street Corp raised its holdings in shares of Y-mAbs Therapeutics by 50.4% in the third quarter. State Street Corp now owns 1,209,781 shares of the company’s stock worth $15,909,000 after buying an additional 405,169 shares during the last quarter. Infinitum Asset Management LLC acquired a new stake in shares of Y-mAbs Therapeutics during the fourth quarter worth $1,218,000. Finally, Paradigm Biocapital Advisors LP lifted its position in Y-mAbs Therapeutics by 3.7% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 4,236,346 shares of the company’s stock worth $33,171,000 after acquiring an additional 150,000 shares during the period. 70.85% of the stock is owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Stock Performance

Shares of Y-mAbs Therapeutics stock opened at $4.50 on Wednesday. The stock has a 50 day moving average price of $5.51 and a 200-day moving average price of $9.34. Y-mAbs Therapeutics has a one year low of $4.25 and a one year high of $17.78. The stock has a market cap of $203.48 million, a price-to-earnings ratio of -8.33 and a beta of 0.65.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). The firm had revenue of $26.50 million for the quarter, compared to the consensus estimate of $26.70 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same quarter last year, the firm earned ($0.02) EPS. Sell-side analysts predict that Y-mAbs Therapeutics will post -0.65 earnings per share for the current fiscal year.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.